[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

723.O2.6 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Donor Lymphocyte Infusion and Other Late Complications After Transplantation

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 2:45 PM-4:15 PM
Douglas Pavilion B (Manchester Grand Hyatt San Diego)
Moderators:
William A Wood, MD, MPH, UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine and Leslie E. Lehmann, MD, Dana-Farber Cancer Institute

Disclosures:
No relevant conflicts of interest to declare.
2:45 PM
Secondary Malignancies After Allogeneic Stem-Cell Transplantation in the Era of Reduced-Intensity Conditioning; The Incidence Is Not Reduced

Avichai Shimoni, MD1*, Noga Shem-Tov, MD1*, Yulia Volchek, MD1*, Ronit Yerushalmi, MD1 and Arnon Nagler2

1Hematology Division and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel
2Hematology Division, Chaim Sheba Medical Center and Tel Aviv University, Guy Weinshtock Multiple Myeloma Foundation, Tel-Hashomer, Israel

3:00 PM
Phase II Study of Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) As First Salvage Therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Final Results From the AZARELA-Trial (NCT-00795548)

Thomas Schroeder, MD1*, Akos Czibere, MD, PhD2, Nicolaus Kröger3*, Uwe Platzbecker, MD4, Gesine Bug5*, Lutz Uharek, Prof., Dr.6*, Thomas Luft7, Christine Wolschke8*, Ingmar Bruns, MD9, Fabian Zohren, MD9*, Roland Fenk10*, Rainer Haas, MD, Prof10* and Guido Kobbe, MD11*

1Hematology, Oncology and Clinical Immunology, Heinrich Heine University Duesseldorf, University Hospital, Duesseldorf, Germany
2Dept. of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany
3Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
4Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
5Medizinische Klinik II, Johann Wolfgang Goethe-Universität, Frankfurt, Germany
6Department of Hematology and Oncology, Charité, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
7Internal Medicine V, University of Heidelberg, Heidelberg, Germany
8Center of Oncology - Bone Marrow Transplantation Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany
10Hematology, Oncology, Heinrich Heine University, Duesseldorf, Germany
11Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Duesseldorf, Germany

3:15 PM
A Phase II Study of Sequential Administration of DLI and Cytokine Induced Killer (CIK) Cells in Patients with Hematologic Malignancies Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation: Preliminary Results

Martino Introna, MD1, Alessandra Algarotti, MD2*, Caterina Micò, MD2*, Anna Grassi, MD2*, Alice Pievani, PhD1*, Gianmaria Borleri1*, Josée Golay, PhD1*, Irene Cavattoni, MD3*, Sergio Cortelazzo, MD3* and Alessandro Rambaldi4

1Laboratory of Cell Therapy "G. Lanzani", USC Hematology, Ospedali Riuniti, Bergamo, Italy
2Hematopoietic Stem Cell Program, USC Hematology, Ospedali Riuniti, Bergamo, Italy
3Dept of Haematology and Bone Marrow Transplantation, Ospedale Centrale Regionale, Bolzano, Italy
4Div of Hematology, Ospedali Riuniti, Bergamo, Italy

3:30 PM
Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

XiaoWen Tang, MD*, Qianlan Zhou*, Zhengming Jin*, Chengcheng Fu*, Chunmei Ye*, Xiaolan Shi*, Xiaohui Hu*, Biyun Peng*, Fan Ye*, Yuxia Lu*, Ziling Zhu*, Yufeng Feng*, Huirong Chang*, Aining Sun* and Wu Depei, MD, PhD

Hematology, The First Affiliated Hosp. of Soochow Univ.,Jiangsu Inst. of Hematology, Suzhou, China

3:45 PM
Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation

Chenhua Yan1*, Daihong Liu1*, Lanping Xu1*, Kaiyan Liu, MD, PhD1, Huan Chen2*, Wei Han1*, Yu Wang2* and Xiaojun Huang1

1Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China
2Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

4:00 PM
Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML

Pramila Krishnamurthy1*, Victoria T Potter, MBBS, FRCPA, FRACP2*, ZiYi Lim2*, Austin G Kulasekararaj3*, Aloysius Y Ho2, Judith C. W. Marsh, Prof MD PhD4, Robin M. Ireland, FRCP, FRCPath5, Stephen Devereux, FRCP, FRCPath, PhD6, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA7 and Ghulam J. Mufti, MD3

1Dept of Haematological Medicine, King's College Hospital, London, United Kingdom
2Department of Haematological Medicine, Kings College Hospital, London, United Kingdom
3Department of Haematological Medicine, King's College Hospital, London, United Kingdom
4Haematological Medicine, King's College Hospital, London, United Kingdom
5Dept of Haematological Medicine, Kings College Hospital NHS Foundation Trust, London, United Kingdom
6Hematological Medicine, Kings College Hospital, London, United Kingdom
7Haematological Medicine, Kings College Hospital, London, United Kingdom

*signifies non-member of ASH